IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S

Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023

Expects preliminary clinical response data from the... | January 8, 2023

Related Keywords

New York ,United States ,Andrew Hall ,Michael Bailey ,Bristol Myers Squibb ,Shabnam Kazmi ,Juliap Gregory ,Harvard Business School ,Linkedin ,Smith College ,Twitter ,Otsuka America Pharmaceuticals ,Nasdaq ,Board Member Of The Prevent Cancer Foundation ,Ovarian Cancer ,Chief Executive Officer ,Diffuse Largeb Cell Lymphoma ,New York City ,Otsuka America ,Asellus Ventures ,Board Member ,Prevent Cancer ,Harvard Business ,Board Chairman ,Imv Inc Stock Exchange ,News ,Information ,Press Release ,Resenting ,Details ,N ,Nitial ,Response ,Data ,Rom ,The ,Ngoing ,Revitalize ,Dlbcl ,Trial ,It ,Conference ,February ,Reliminary ,Linical ,Rom Imv Ca44974l3011 ,